

"Express Mail" mailing label number EL 832897056 US

Date of Deposit March 26, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Arlington, VA 22202.

DULKEN Thomas

Printed Name

Dulken Thomas

Signature

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

The Accompanying Application

Applicants : Arbuthnot, et al.)

)

For : BENZOTHIOPHENES, FORMULATIONS)
CONTAINING SAME, AND METHODS)

)

Docket No. : X-10443F)

)

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents

Arlington, VA 22202

Sir:


As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation in an Application" on a modified Form PTO-1449.

As permitted by 37 C.F.R. §1.98(d), Applicants refer to application Serial No. 08/812,896 filed March 10, 1997 for copies of the listed references.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

Applicants request consideration of this information.

Respectfully submitted,



Gilbert T. Voy
Attorney for Applicant
Registration No. 43,972
Phone: 317-276-2966

Eli Lilly and Company
Patent Division/GTV
Lilly Corporate Center
Indianapolis, Indiana 46285

March 25, 2004

FORM PTO 1449 (modified)		Atty. Docket No. X10443F	Serial No
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicants Arbuthnot, et al.	
		Filing Date	Group

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Sub-class	Filing Date If Appropriate
	AA	4,133,814	1/9/79	Jones, et al.			
	AB	4,391,755	7/5/83	Wang, et al.			
	AC	4,515,805	5/7/85	Newman			
	AD	4,605,517	8/12/86	Riley, et al.			
	AE	5,494,920	2/27/96	Glasebrook, et al.			
	AF	5,494,929	2/27/96	Greese			
	AG	5,532,254	7/2/96	Bowling			
	AH	4,418,068	11/29/83	Jones			
	AI	5,441,964	8/15/95	Bryant, et al.			
	AJ	5,629,425	5/13/97	Labell, et al.			
	AK	5,202,129	4/1993	Samejima, et al.			
	AL	5,731,327	3/1998	Luke			9/1994
	AM	5,811,120	9/1998	Gibson, et al.,			3/1994
	AN	5,811,120	9/1998	Gibson, et al., F.D. 03-1994			
	AO	6,458,811	10/2002	Arbuthnot, et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub-class	Translation	
							yes	no
	BA	EP 108606A1	11/2/83	EPO				
	BB	EP 674903A1	10/4/95	EPO				
	BC	EP 670162A1	2/28/95	EPO				

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

FORM PTO 1449 (modified)			Atty. Docket No. X10443F	Serial No
INFORMATION DISCLOSURE CITATION IN AN APPLICATION			Applicant Arbuthnot, et al.	
			Filing Date	Group
	CA		Lieberman, et al., "Pharmaceutical Dosage Forms" Marcel Dekker Inc., p107-117, 186-187, 1980	
	CB		Omelczuk, et al., "Influence of micronization on the compaction properties of an investigational drug using tabletting index analysis" Eur. J. Pharm. Biopharm., v. 43, 95-1 OC., 1997	
	CC		West, "Blocky Diamond Particles from Diamond Powder" CA 73:57576	
	CD		Jones, J.Med.Chem., 27:1057-1066, 1984	
	CE		Pharmaceutics, Chief Editor: Mr. XiNiao Zhu, the People's Health Publishers, third edition, July 1994	
	CI			
	CJ			
	CK			
	CL			
	CM			
	CN			
	CO			
	CP			
	CQ			
	CR			
EXAMINER			DATE CONSIDERED	
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.</p>				